Study | N-3 PUFA Dose (g/d) | % Change in serum TG levels | Duration (wks) | Additional Supplement (g/d) | Study | N-3 PUFA Dose (g/d) | % Change in serum TG levels | Duration (wks) | Additional Supplement (g/d) |
---|---|---|---|---|---|---|---|---|---|
Normolipidemic Subjects - EPA and/or DHA Supplements | Moderately Hyperlipidemic Subjects – EPA and/or DHA Supplements | ||||||||
Cazzola [64] | Â | Â | Â | Â | Buckley [59] | Â | Â | Â | Â |
 Group A | 4.05 | −30* | 12 |  | Group A | 4.9 | −8* | 4 |  |
 Group B | 4.05 | −25* | 12 |  | Group B | 4.8 | −22* | 4 |  |
 Group C | 2.7 | −25* | 12 |  | Laidlaw [51] |  |  |  |  |
 Group D | 2.7 | −33* | 12 |  | Group A | 4 | −40* | 4 |  |
 Group E | 1.35 | −22* | 12 |  | Group B | 4 | −39* | 4 | 1 g of γ-linolenic acid |
 Group F | 1.35 | −33* | 12 |  | Group C | 4 | −35* | 4 | 2 g of γ-linolenic acid |
Damsgaard [56] |  |  |  |  | Group D | 4 | −7 | 4 | 4 g of γ-linolenic acid |
 Group A | 3.25 | −51* | 8 | Low LA diet | Di Stasi [54] |  |  |  |  |
 Group B | 3.25 | −19* | 8 | High LA diet/Olive Oil | Group A | 4 | −20 | 12 |  |
Nilsson [46] | 3 | −12* | 5 |  | Group B | 2 | −15 | 12 |  |
Hlais [45] | Â | Â | Â | Â | Group C | 1 | 9 | 12 | Â |
 Group A | 2.95 | −10 | 6 | 8 g of Sunflower Oil | Stark [55] | 4 | -26* | 4 |  |
 Group B | 2.95 | −2 | 12 | 8 g of Sunflower Oil | Offman [50] |  |  |  |  |
 Group C | 1.47 | −15* | 6 |  | Group A | 3.3 | −8 | 2 |  |
 Group D | 1.47 | 6 | 6 | 8 g of Sunflower Oil | Group B | 3 | −21 | 2 |  |
 Group E | 1.47 | −12 | 12 |  | Vanschoonbeek [53] | 3 | −10* | 4 |  |
 Group F | 1.47 | 1 | 12 | 8 g of Sunflower Oil | Ciubotaru [49] |  |  |  |  |
 Group G | 0.74 | −4 | 6 | 8 g of Sunflower Oil | Group A | 2.9 | −26* | 5 |  |
 Group H | 0.74 | −12 | 12 | 8 g of Sunflower Oil | Group B | 1.45 | −4 | 5 | 7 g of Safflower Oil |
Brady [57] |  |  |  |  | Stark [61] | 2.8 | −20* | 4 |  |
 Group A | 2.5 | −25* | 6 | Moderate LA diet/Olive Oil | Lovegrove [48] | 2.5 | −31* | 12 |  |
 Group B | 2.5 | −20* | 6 | High LA diet - Corn Oil | Sanders [44] |  |  |  |  |
Wu [62] | 2.4 | −18* | 6 |  | Group A | 1.8 | −17* | 52 |  |
Sanders [60] | 2.1 | −21 | 4 |  | Group B | 0.9 | 0 | 52 |  |
Rizza [47] | 2 | −26* | 12 |  | Group C | 0.45 | 0 | 52 |  |
Geppert [63] | 0.94 | −23* | 8 |  | Mann [52] |  |  |  |  |
Kaul [58] |  |  |  |  | Group A | 1.05 | −21* | 2 |  |
 Group A | 0.61 | 0 | 12 |  | Group B | 1.02 | −25* | 2 |  |
 |  |  |  |  | Fakhrzadeh [43] | 0.3 | −2 | 26 |  |
Normolipidemic Subjects - ALA Supplements | Â | Â | Â | Â | Â | ||||
Kaul [58] | Â | Â | Â | Â | Â | Â | Â | Â | Â |
 Group B | 1.02 | 0 | 12 | Flaxseed Oil; 0.28 g of LA |  |  |  |  |  |
 Group C | 0.37 | 15 | 12 | Hempseed Oil; 1.02 g of LA |  |  |  |  |  |